Event: IASLC TTLC 2024

0:00:20

Terri Conneran Highlights the Importance of Research Released at IASLC's TTLC

0:00:45

How IASLC's Conference on Targeted Therapies Moves the Needle in Lung Cancer Research

0:00:35

Current standard of care for inoperable stage III NSCLC

0:00:43

Developments in the management of EGFR-mutated NSCLC

0:01:44

Overview and advances in tumor treatment fields (TTFields)

0:01:16

The future of TRK inhibitors in lung cancer treatment

0:03:40

The role of DLL3-directed agents in treating SCLC

0:02:41

Why should consolidation radiotherapy be used in stage IV lung cancer?

0:13:18

Updates in the management of lung cancer with ADCs

0:08:06

An introduction to the MAPK signaling pathway and pan-RAF inhibitors

0:05:43

Novel immunotherapy combinations for SCLC

0:01:53

Assessing NSCLC treatments in under-represented patient populations

0:02:39

Targeting NTRK and NRG in lung cancer treatment

0:02:08

Racial disparities in lung cancer biomarker testing and clinical trial recruitment

0:01:19

Assessing increased creatinine levels in patient with lung cancer receiving TKIs

0:01:18

Combination therapies involving KRAS G12C inhibitors in lung cancer

0:01:52

Management options for patients with type II/III BRAF-mutated lung cancer

0:01:54

Novel non-KRAS G12C inhibitors in solid tumors

0:02:18

Elucidating the causes behind low testing rates in lung cancer

0:02:41

Curative and palliative radiation in patients with NSCLC with cachexia

0:02:45

Initial chemotherapy options for advanced and metastatic NUT carcinoma

0:03:25

Characterization and diagnosis of NUT carcinoma

0:02:31

Targeting SMARCA4 mutations in lung cancer

0:01:44

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterations